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Introduction {#sec005}
============

Head and neck squamous cell carcinoma (HNSCC) occurs in the oral cavity, oropharynx, hypopharynx and larynx. HNSCC is the sixth most common cancer worldwide and the fifth leading cause of cancer death. Over 500,000 HNSCC cases occur each year \[[@pone.0122302.ref001]\]. However, the five-year survival of patients with HNSCC was only 40--50% \[[@pone.0122302.ref002]\].

The pathogenesis of HNSCC is a multistep and multifactorial complex mechanism containing a variety of genetic and epigenetic abnormalities, signal transduction, apoptosis, angiogenesis, and cell cycle regulation \[[@pone.0122302.ref003]\]. Epigenetic inactivation of the gene resulted from the methylation of CpG islands in promoters is one of the most frequent events in human tumors. The *p16* ^*INK4a*^ gene plays a key role in cell cycle regulation and is located on chromosome 9p21 which consisting of three exons and two introns, spanning approximately 8.5 kb \[[@pone.0122302.ref004], [@pone.0122302.ref005]\]. It is one of the most frequently altered genes observed in various human tumors \[[@pone.0122302.ref006], [@pone.0122302.ref007]\]. P16 prevents the inactivation of retinoblastoma (Rb) protein by inhibiting the cyclin dependent kinases (CDks) and retinoblastoma (Rb) pathway plays an important role in apoptosis and cell cycle regulation \[[@pone.0122302.ref008]\]. More studies have shown that methylation of *p16* ^*INK4a*^ promoter may play an important role in the development of HNSCC.

Some studies have reported differences in the methylation frequencies of *p16* ^*INK4a*^ promoter between cancer and non-cancerous. However, the results are inconsistent. Therefore, the aims of this meta-analysis are to consolidate the available data and to better identify the association between *p16* ^*INK4a*^ promoter methylation and HNSCC.

Materials and Methods {#sec006}
=====================

Search Strategy {#sec007}
---------------

Relevant studies were identified from the online electronic databases (PubMed, Ovid, ISI Web of Science, and EMBASE) using the search terms: (squamous cell carcinoma or cancer) and (oropharyngeal or oropharynx or head and neck or tonsil) AND (p16 methylation). The search was limited to English language paper. The search results were updated until August 20, 2014.

Study Selection {#sec008}
---------------

A study included in the meta-analysis had to meet the following criteria: (1) studies with evaluating the association between *p16* ^*INK4a*^ promoter methylation frequency and HNSCC, (2) case-control study or providing the case and the control cases, (3) providing the *p16* ^*INK4a*^ promoter methylation frequency in case and control groups, (4) specimens of HNSCC were surgically respected primary tumor sample. Firstly, the titles and abstracts of initial searching articles were evaluated for whether it met the inclusion criteria. Then all potentially relevant articles were evaluated on full-text paper. If the results of a study were published more than once, only the most complete and up-to-date information were included in the meta-analysis. The study selection process was shown in [Fig 1](#pone.0122302.g001){ref-type="fig"}. Finally, a total of 21 studies (PubMed 13, Web of Science 7, Ovid 1) which contain 1155 cases and 1017 controls were included in our meta-analysis.

![Selection of studies in the meta-analysis.](pone.0122302.g001){#pone.0122302.g001}

Data Extraction and Quality Assessment {#sec009}
--------------------------------------

Three reviewers (Hao Shi, Changmei Gu, and Ruiwei Meng) independently reviewed the included articles. The following information was extracted from the included studies: first author's name, year of publication, study population, sample size, sample type in case and control group, the state of the individual of the control group, the number of people with *p16* ^*INK4a*^ methylation in the case and control groups, the number of the case and control groups. All the detailed information of the included studies was checked by three reviewers (Meixia Lu, Xiong Chen, and Cheng Lu) as described in the Cochrane Handbook for systematic reviews.

Statistical Methods {#sec010}
-------------------

The pooled odds ratios (ORs) and their 95% confidence intervals (CIs) were used to assess the strength of the association between *p16* ^*INK4a*^ promoter methylation and HNSCC. The *x* ^2^-based Cochran Q statistic test and *I* ^2^ statistics were used to test the between-study heterogeneity \[[@pone.0122302.ref009]\]. When *P*\<0.05 for the Q statistic or *I* ^2^ ≥50%, the heterogeneity was considered significant and a random-effects model was used to calculate the pooled ORs. Otherwise, a fixed-effects model was applied. The meta-regression (method = restricted maximum-likelihood estimator) was employed to explore the source of heterogeneity. And the subgroup analysis was performed for further evaluation of the source of heterogeneity. The contribution of each study to the final results of the meta-analysis was evaluated according to the sensitivity analysis. Begg's funnel plot \[[@pone.0122302.ref010]\] and Egger's test \[[@pone.0122302.ref011]\] were used to assess the publication bias. The fail-safe number \[[@pone.0122302.ref012]\] was also employed to assess the publication bias. In the study, all the *P* values are two sides with a significant level at 0.05. When the individual studies have cells with zero counts, the default is to add 0.5 to all zero counts in the Meta package. All statistical analyses were performed with the Meta package (version 3.0--1; [http://CRAN.R-project.org/package=meta](http://cran.r-project.org/package=meta)) in R (version 3.10; <http://www.r-project.org/>).

Results {#sec011}
=======

Study Characteristics {#sec012}
---------------------

The comprehensive search and selection procedures of literature were displayed in [Fig 1](#pone.0122302.g001){ref-type="fig"} for evaluating the association between *p16* ^*INK4a*^ promoter methylation frequency and HNSCC. A total of 21 studies with 1155 cases and 1017 controls were included in the meta-analysis. 397 studies were initially identified by searching the electronic databases. 63 potentially relevant studies were retrieved for further evaluation after removing 82 duplicated articles, 59 reviews or meeting reviews, 9 cell lines and animal studies, 175 irrelevant articles, and 9 papers that did not have full text versions. 32 studies without a control group, 8 studies without *p16* ^*INK4a*^ promoter methylation data, and 2 studies without tissue in the case group were excluded from full-text review. Finally, 21 studies were included in our meta-analysis. Ten studies were of Asian subjects and eleven studies were of Caucasian subjects. The control group included HNSCC patients, benign disease patients, and healthy people. And the sample type of control group included tissue, serum, blood, and saliva. The methylation detection method of *p16* ^*INK4a*^ in HNSCC and control included 16 studies used methylation-specific polymerase chain reaction (MSP), three studies used real-time quantitative MSP (QMSP), one study used PCR-based methylation-sensitive restriction analysis (MSRA), and one study used pyrosequencing (Pyro). Six studies \[[@pone.0122302.ref013]--[@pone.0122302.ref018]\] were the methylated CpG islands of promoter and fifteen studies \[[@pone.0122302.ref019]--[@pone.0122302.ref033]\] were the methylation of promoter. Study characteristics were summarized in [Table 1](#pone.0122302.t001){ref-type="table"}.

10.1371/journal.pone.0122302.t001

###### Characteristics of studies included in the study characteristics of included studies.

![](pone.0122302.t001){#pone.0122302.t001g}

                                                          Case   Control        Control   Control       
  -------------------------------------- ------ --------- ------ --------- ---- --------- --------- --- --------
  Kis\[[@pone.0122302.ref019]\]          2014   Hungary   14     36        3    65        MSP       H   saliva
  Bhatia\[[@pone.0122302.ref020]\]       2014   India     62     14        33   36        MSP       H   tissue
                                                                           18   52        MSP       H   blood
  Dang\[[@pone.0122302.ref021]\]         2013   China     6      6         5    25        MSP       H   tissue
  Demokan\[[@pone.0122302.ref022]\]      2011   Turkish   41     19        22   55        QMSP      A   tissue
  Wong\[[@pone.0122302.ref023]\]         2011   Taiwan    43     21        20   64        MSP       H   tissue
  Weiss\[[@pone.0122302.ref024]\]        2011   Germany   4      47        2    29        MSP       H   tissue
  Laytragoon\[[@pone.0122302.ref013]\]   2010   Sweden    39     2         15   3         MSP       A   tissue
  Kaur\[[@pone.0122302.ref025]\]         2010   India     44     48        5    43        QMSP      A   tissue
                                                                           0    30        QMSP      H   serum
  Su\[[@pone.0122302.ref026]\]           2010   Taiwan    10     20        3    27        QMSP      A   tissue
  Steinmann\[[@pone.0122302.ref014]\]    2009   Germany   32     22        6    17        MSP       A   tissue
  Ghosh\[[@pone.0122302.ref027]\]        2009   India     9      54        7    33        MSRA      H   tissue
  Righini\[[@pone.0122302.ref033]\]      2007   French    20     70        0    30        MSP       A   tissue
                                                                           0    30        MSP       H   saliva
                                                                           16   60        MSP       A   saliva
  Martone\[[@pone.0122302.ref028]\]      2007   Italy     4      16        3    8         MSP       A   tissue
  Shaw\[[@pone.0122302.ref015]\]         2006   UK        22     58        1    25        Pyro      A   tissue
  Maruya\[[@pone.0122302.ref016]\]       2004   USA       10     22        1    31        MSP       A   tissue
                                                                           2    4         MSP       H   tissue
  Kulkarni\[[@pone.0122302.ref029]\]     2004   India     40     20        30   30        MSP       A   tissue
                                                                           0    20        MSP       H   saliva
  Wong\[[@pone.0122302.ref030]\]         2003   China     36     37        5    24        MSP       A   tissue
                                                                           4    16        MSP       H   serum
  Weber\[[@pone.0122302.ref031]\]        2003   Germany   16     34        12   30        MSP       H   tissue
  Nakahara\[[@pone.0122302.ref017]\]     2001   Japan     16     16        0    32        MSP       A   tissue
  Rosas\[[@pone.0122302.ref032]\]        2001   USA       14     16        11   3         MSP       A   saliva
                                                                           1    29        MSP       H   saliva
  Sanchez\[[@pone.0122302.ref018]\]      2000   USA       26     69        8    18        MSP       A   serum

M: *p16* ^*INK4a*^ promoter methylated; U: *p16* ^*INK4a*^ promoter unmethylated

\#: A: Autologous (the control from the HNSCC themselves); H: Heterogeneous (the control from other individuals, including blood, serum, saliva or tissue).

Combining Results of Included Studies {#sec013}
-------------------------------------

The combining result showed the association of *p16* ^*INK4a*^ promoter methylation with HNSCC risk in [Fig 2](#pone.0122302.g002){ref-type="fig"}. A random-effects model was employed because of the significant heterogeneity was observed among the included studies (*I* ^*2*^ = 60.1%, Q = 50.07, *P*\<0.001). In the overall meta-analysis, *p16* ^*INK4a*^ promoter methylation frequency was significantly associated with HNSCC (Summary OR was 3.37, 95%CI = 2.32--4.90) ([Fig 2](#pone.0122302.g002){ref-type="fig"}).

![Summary estimates for *p16^INK4a^* promoter methylation frequency associated with HNSCC by meta-analysis.](pone.0122302.g002){#pone.0122302.g002}

Sensitivity Analysis {#sec014}
--------------------

A sensitivity analysis was performed by omitting a single study and calculating the pooled OR for the remaining studies under the random-effect model to assess the effects of each individual study on the pooled OR. The results of sensitivity analysis were summarized in the [Table 2](#pone.0122302.t002){ref-type="table"}. According to sensitivity analysis the odds ratio ranged from 3.10 (95%CI = 2.16--4.46) to 3.65 (95%CI = 2.55--5.23) by omitting a single study under the random-effect model. The sensitivity analysis indicated that the pooled OR between *p16* ^*INK4a*^ promoter methylation and HNSCC were reliable and stable.

10.1371/journal.pone.0122302.t002

###### Sensitivity analysis of pooled OR for *p16^INK4a^* methylation and HNSCC under the random-effects model.

![](pone.0122302.t002){#pone.0122302.t002g}

  Study omitted      OR (95%CI)        *P* for heterogeneity   *tau* ^*2*^   *I* ^*2*^ (%)
  ------------------ ----------------- ----------------------- ------------- ---------------
  Kis, 2014          3.27(2.21;4.74)   \<0.001                 0.41          60.50%
  Bhatia, 2014       3.29(2.21;4.89)   \<0.001                 0.45          61.20%
  Dang, 2013         3.32(2.26;4.89)   \<0.001                 0.43          61.90%
  Weiss, 2011        3.48(2.38;5.09)   \<0.001                 0.42          61.10%
  Wong, 2011         3.22(2.18;4.74)   \<0.001                 0.42          59.20%
  Demokan, 2011      3.27(2.20;4.85)   \<0.001                 0.45          60.70%
  Laytragoon, 2010   3.36(2.29;4.93)   \<0.001                 0.43          62.00%
  Su, 2010           3.33(2.26;4.92)   \<0.001                 0.44          61.90%
  Kaur, 2010         3.10(2.16;4.46)   \<0.001                 0.34          54.90%
  Steinmann, 2009    3.34(2.25;4.94)   \<0.001                 0.45          62.00%
  Ghosh, 2009        3.63(2.53;5.22)   \<0.001                 0.34          55.60%
  Martone, 2007      3.54(2.44;5.14)   \<0.001                 0.39          59.20%
  Righini, 2007      3.52(2.38;5.20)   \<0.001                 0.43          59.70%
  Shaw, 2006         3.29(2.25;4.80)   \<0.001                 0.42          61.20%
  Kulkarni, 2004     3.38(2.26;5.06)   \<0.001                 0.48          62.10%
  Maruya, 2004       3.31(2.25;4.87)   \<0.001                 0.43          61.70%
  Weber, 2003        3.59(2.47;5.22)   \<0.001                 0.37          57.20%
  Wong, 2003         3.32(2.23;4.94)   \<0.001                 0.45          61.80%
  Nakahara, 2001     3.23(2.25;4.65)   \<0.001                 0.37          58.50%
  Rosas, 2001        3.45(2.33;5.10)   \<0.001                 0.44          61.60%
  Sanchez, 2000      3.65(2.55;5.23)   \<0.001                 0.33          54.10%

Meta-regression and Subgroup Analysis {#sec015}
-------------------------------------

As the significant heterogeneity across the studies was found (*I* ^*2*^ = 60.1%, Q = 50.07, *P*\<0.001), the meta-regression was employed to explore potential sources of heterogeneity. We conducted a multiple regression model with six variables (i.e. Population subgroup, publication year, case sample size, control type, control sample type, and method). No source of significant heterogeneity was found ([Table 3](#pone.0122302.t003){ref-type="table"}). The subgroup analysis was performed to further evaluate the source of the heterogeneity according to populations, case sample size, control type, control sample type, and method.

10.1371/journal.pone.0122302.t003

###### Mixed-effects model of Meta-regression analysis.

![](pone.0122302.t003){#pone.0122302.t003g}

                                 95%CI          
  ---------------------- ------- ------- ------ ------
  Population             -0.75   -1.74   0.24   0.14
  Publication year       0.05    -0.06   0.15   0.39
  Case sample size       -0.24   -1.19   0.70   0.61
  Method\$Pyro           2.09    -0.76   4.93   0.15
  Method\$QMSP           0.89    -0.43   2.20   0.19
  Control style          0.38    -0.58   1.34   0.54
  Control sample types   -0.83   -1.81   0.14   0.09

The OR for was 4.76 (95%CI = 3.00--7.54) in Asians under the random-effects model, and 2.25 (95%CI = 1.61--3.13) in Caucasians under the fixed-effects model. With the case sample size, the OR for was 3.33 (95%CI = 1.68--6.60) in the \>60 case group under the random-effects model, and 3.59 (95%CI = 2.65--4.87) in the ≤60 case group under the fixed-effects model. In the subgroup analysis of the control type, the frequencies of *p16* ^*INK4a*^ promoter methylation in the autologous group were higher than those in the heterogeneous group including benign disease and healthy individuals under the random-effects model (Autologous: 3.14, 95%CI = 1.76--5.59; Heterogeneous: 4.62, 95%CI = 2.43--8.79; respectively). Subgroup analysis of the control sample type showed that the frequencies of *p16* ^*INK4a*^ promoter methylation in the Non-tissue group (control sample type: serum or saliva) were higher than those in the tissue group (control sample type: tissue) under the random-effects model (Non-tissue: 5.92, 95%CI = 2.94--15.30; Tissue: 3.43, 95%CI = 2.25--5.24; respectively). For the methylation detection method of *p16* ^*INK4a*^ promoter, Ghosh \[[@pone.0122302.ref027]\] used PCR-based methylation-sensitive restriction analysis (MSRA) and we have put the study classified as MSP group. The OR was 7.30 (95%CI = 4.26--12.48) in the QMSP group under the fixed-effects model, 2.83 (95%CI = 1.89--4.23) in the MSP group under the random-effects model, and 9.48 (95%CI = 1.21--74.26) in the Pyro group. All results of subgroup analysis were summarized in [Table 4](#pone.0122302.t004){ref-type="table"}.

10.1371/journal.pone.0122302.t004

###### Subgroup analysis of the association between *p16^INK4a^* promoter methylation and HNSCC.

![](pone.0122302.t004){#pone.0122302.t004g}

                                                               Case   Control   M-H pooled OR[†](#t004fn001){ref-type="table-fn"}   D+L pooled OR[‡](#t004fn002){ref-type="table-fn"}   Heterogeneity                                             
  ------------------------------------------------------------ ------ --------- --------------------------------------------------- --------------------------------------------------- -------------------- -------------------- ------ -------- ------
  Total                                                        508    1155      215                                                 1017                                                3.58 (2.89--4.44)    3.37 (2.32--4.90)    60.1   \<0.01   0.41
  Population subgroup                                                                                                                                                                                                                             
      Asians                                                   307    562       134                                                 570                                                 4.99 (3.77--6.62)    4.76 (3.00--7.54)    55.3   0.02     0.28
      Caucasians                                               201    593       81                                                  447                                                 2.25 (1.61--3.13)    2.26 (1.39--3.66)    42.8   0.06     0.26
  Case sample size                                                                                                                                                                                                                                
      ≤60                                                      246    522       116                                                 524                                                 3.59 (2.65--4.86)    3.38 (2.21--5.17)    37.5   0.08     0.21
      \>60                                                     262    633       99                                                  493                                                 3.58 (2.65--4.84)    3.33 (1.68--6.60)    77.3   \<0.01   0.72
  Control style                                                                                                                                                                                                                                   
      Autologous                                               392    879       126                                                 516                                                 3.12 (2.38--4.08)    3.14 (1.76--5.59)    69.1   \<0.01   0.78
      Heterogeneous                                            353    838       90                                                  531                                                 4.93 (3.61--6.72)    4.62 (2.43--8.79)    66.6   \<0.01   0.86
  Control sample type[^\$^](#t004fn003){ref-type="table-fn"}                                                                                                                                                                                      
      Tissue                                                   463    980       171                                                 687                                                 3.84 (2.99--4.93)    3.43 (2.25--5.24)    55.3   \<0.01   0.40
      Non-tissue                                               344    813       63                                                  430                                                 4.54 (3.29--6.25)    5.92 (2.29--15.30)   80.5   \<0.01   2.01
  Method                                                                                                                                                                                                                                          
      Pyro                                                     22     80        1                                                   26                                                  9.48 (1.21--74.26)   9.48 (1.21--74.26)   \-     \-       \-
      QMSP                                                     95     182       30                                                  185                                                 7.30 (4.26--12.48)   7.00 (3.70--13.21)   20.9   0.28     0.07
      MSP                                                      391    893       184                                                 806                                                 3.01 (2.38--3.82)    2.83 (1.89--4.23)    58.0   \<0.01   0.37

†: the fixed-effects model

‡: the random-effects model

\$: non-tissue: serum, saliva and blood

Publication bias {#sec016}
----------------

Begg's funnel plot, Egger's test, and the fail-safe number were performed to assess the publication bias of the literature. The shape of the Begg's funnel plot in [Fig 3](#pone.0122302.g003){ref-type="fig"} showed a possible asymmetry, but the Egger's test did not detect publication bias (*P* = 0.25). The fail-safe number (*Z* = 54.20, N~fs0.05~ = 1071.09, N~fs0.01~ = 520.05) also did not display statistical evidence for publication bias.

![The Begg's funnel plot for assessment of publication bias in the meta-analysis.](pone.0122302.g003){#pone.0122302.g003}

Discussion {#sec017}
==========

Hypermethylation of the tumor suppressor gene (*TSG*) promoter can be found in various cancers and induce the silencing of tumor suppressor genes in the process of carcinogenesis. The *p16* ^*INK4a*^ is an important tumor suppressor and DNA repair genes with a major negative regulator of critical tumor pathway \[[@pone.0122302.ref034]\] and the pl6/cyclin D/CDK/pRB pathway is also prominent in many epithelial malignancies \[[@pone.0122302.ref035]\]. Inactivation of *p16* ^*INK4a*^ induced by aberrant hypermethylation plays a role in the process of carcinogenesis in various cancers (i.e. Lung, hepatocellular, gastric, and breast cancer) \[[@pone.0122302.ref036]--[@pone.0122302.ref039]\].

The current meta-analysis assessed the association between *p16* ^*INK4a*^ promoter methylation and HNSCC, which included 21 studies with 1155 cases and 1017 controls. The frequency of *p16* ^*INK4a*^ promoter methylation in tumor was 43.98% and 21.14% in control. The pooled odds ratio under a random-effect model was 3.37 (95%CI = 2.32--4.90) in the cancer cases versus the controls. The result identified that methylation of *p16* ^*INK4a*^ promoter had 3.37 fold increased risks of HNSCC compared with the control group.

In subgroup analysis, the OR for was 4.76 (95%CI = 3.00--7.54) in Asians under the random-effects model, and 2.25 (95%CI = 1.61--3.13) in Caucasians under the fixed-effects model. The association between *p16* ^*INK4a*^ promoter methylation and HNSCC in Asians was stronger than that in Caucasians. Similarly, Kaur's study observed that the frequency of *p16* ^*INK4a*^ promoter methylation (47.8%) in Indian cohort was higher than that in North-American cohort (37.5%) \[[@pone.0122302.ref025]\]. In method subgroup, The OR was 7.30 (95%CI = 4.26--12.48) in the QMSP group under the fixed-effects model, 2.83 (95%CI = 1.89--4.23) in the MSP group under the random-effects model, and 9.48 (95%CI = 1.21--74.26) in the Pyro group. In the past few years, several methods were developed to detect aberrant gene methylation (e.g. MSP, QMSP, Pyro, etc.). MSP is a simple, sensitive, and specific method for detecting the methylation status of CpG rich region \[[@pone.0122302.ref040]\]. However, MSP and QMSP require particular gene sequence information for the design of PCR primers \[[@pone.0122302.ref041]\]. The different primers may have an impact on the results. MSP (a nonquantitative nonfluorometric PCR method) could not detect low levels of promoter methylation, unlike QMSP which can detect up to 1/1000 methylated alleles \[[@pone.0122302.ref042]\]. Pyro is a much more accurate and quantitative method in detecting gene methylation level and is based on DNA sequence analysis. The detection method of gene methylation and primers selected from regions of the same CpG island and gene promoter was different in each study. These factors may have different sensitivities and specificities in detection of gene methylation \[[@pone.0122302.ref043]\]. In addition, the degrees of heterogeneity of tumors are different, either as infiltrating normal cells or different clones of tumor cells. This will influence the results of methylation analyses. These reasons may lead to different results and be a source of heterogeneity. In the subgroup analysis of sample size, control type, and control sample type, significant associations were observed for all subgroups.

Some studies found that reduced p16 expression in 55--89% of oral and oropharyngeal SCC \[[@pone.0122302.ref044]--[@pone.0122302.ref046]\]. The unusual p16 protein expression is probably due to different demographical and clinicopathological characteristics, HPV-driven HNSCC cases, or gene hypermethylation, etc \[[@pone.0122302.ref047]--[@pone.0122302.ref049]\]. Demokan's study noted that promoter hypermethylation levels were associated with decreased p16 expression in the tumor samples \[[@pone.0122302.ref022]\]. Interestingly, Annette's study found that 95% (110/116) of OSCC did not overexpress p16, while *p16* ^*INK4a*^ promoter methylation was 18% (20/113) \[[@pone.0122302.ref050]\]. Human papillomaviruses (HPV) is also an important factor in carcinogenesis of HNSCC. It is well documented that HPV infection induced overexpression p16 in OSCCs \[[@pone.0122302.ref051]--[@pone.0122302.ref054]\], however, Weiss's study did not show any significantly difference frequencies of *p16* ^*INK4a*^ promoter methylation between HPV16 positive cancer and HPV16 negative cancer \[[@pone.0122302.ref024]\]. Then, future studies are needed to evaluate the interaction of HPV16 infection and p16INK4a promoter methylation on expression p16 in HNSCC.

There were some limitations in the meta-analysis. Firstly, a significant heterogeneity across the studies was found (*I* ^*2*^ = 60.1%, Q = 50.07, *P*\<0.001) in the meta-analysis. According to meta-regression and subgroup analysis, no sources of heterogeneity were founded. Therefore, some source of heterogeneity may exist among studies. Secondly, we do not study the association between *p16* ^*INK4a*^ promoter methylation and disease characteristics (stage, metastasis, relapse and so on) of HNSCC. According to study the association between *p16* ^*INK4a*^ promoter methylation and disease characteristics, the special role of *p16* ^*INK4a*^ promoter methylation in the carcinogenic process of HNSCC may be found.

In conclusion, the results of the meta-analysis showed aberrant methylation of *p16* ^*INK4a*^ promoter was found to be associated with HNSCC, which suggested that promoter methylation of *p16* ^*INK4a*^ may be a potential biomarker in the carcinogenic process of HNSCC.
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